Apilimod mesilate

阿吡莫德甲磺酸盐

Report date: 2026/04/19 20:00:14
NME

Base Information

Drug NameApilimod mesilate
Drug Alias Name阿匹莫德甲磺酸盐Apilimod mesylate甲磺酸阿吡莫德Apilimod dimesilateapilimod +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-12 inhibitors1-phosphatidylinositol 3-phosphate 5-kinase inhibitors
TargetsInterleukin-121-phosphatidylinositol 3-phosphate 5-kinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Common Variable ImmunodeficiencyAmyotrophic Lateral Sclerosis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOrphAI Therapeutics IncMadrigal Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrphAI Therapeutics Inc
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Madrigal Pharmaceuticals Inc
Active IndicationsAmyotrophic Lateral SclerosisLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Common Variable ImmunodeficiencyCrohn Disease +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG